ACAD ACADIA PHARMACEUTICALS INC
Company Analysis
Latest News
ACAD Head of R&D Departs, Will Serve as Consultant Through Year-End
Acadia Pharmaceuticals confirmed that Elizabeth H.Z. Thompson, Ph.D., Executive Vice President and Head of Research and Development, has officially retired...
🟢 ACADIA Pharmaceuticals is trading 5.9% up in pre-market on healthcare-sector rotation
ACADIA Pharmaceuticals is trading at $20.88, up +5.94%, in pre-market as healthcare stocks attract buying amid a rotation away from AI and technology...
🔴 ACADIA Pharmaceuticals is trading 4.02% down with no clear intraday catalyst
ACADIA Pharmaceuticals is trading 4.02% down at $18.63 on October 13, 2026, with no new company-specific announcement clearly explaining the intraday...
🔴 ACADIA Pharmaceuticals is trading 4.04% down today after RADIANT missed primary endpoint
ACADIA Pharmaceuticals is trading at $19.84 (-4.04%) as the RADIANT 60 mg dose narrowly missed the primary endpoint (p=0.0603). - The dose showed nominal...
🟢 ACADIA Pharmaceuticals is trading 8.8% up in pre-market
ACADIA Pharmaceuticals is trading at $22.50, up 8.80% in pre-market, with no fresh catalyst established by the available evidence. - No new September 28...
🔴 ACADIA Pharmaceuticals is trading 4.1% down today after Phase 2 RADIANT study narrowly misses primary endpoint
ACADIA Pharmaceuticals is trading 4.1% down at $21.27 after September 24, 2026, Phase 2 RADIANT results for remlifanserin narrowly missed the primary endpoint...
Acadia to Advance Alzheimer's Drug to Phase 3 on Mixed Phase 2 Trial Results
Acadia Pharmaceuticals announced topline results from its Phase 2 RADIANT study of remlifanserin for Alzheimer's disease psychosis (ADP). The 60 mg dose...
🔴 ACADIA Pharmaceuticals is trading 10.6% down today after Alzheimer’s psychosis trial misses primary endpoint
ACADIA Pharmaceuticals is trading 10.6% down at $22.73 after remlifanserin narrowly missed the primary endpoint in the Phase 2 RADIANT Alzheimer’s disease...
Acadia's Alzheimer's Drug Stumbles at the Finish Line — Can a $4 Billion Pipeline Bet Survive a Near-Miss?
Shares of Acadia Pharmaceuticals tumbled 8.1% to $23.36 this morning after the company's experimental Alzheimer's psychosis drug narrowly failed to prove...
🔴 ACADIA Pharmaceuticals is trading 9.8% down in pre-market after RADIANT primary endpoint narrowly missed significance
ACADIA Pharmaceuticals is trading at $23.36, down 9.8%, after remlifanserin narrowly missed statistical significance on the Phase 2 RADIANT primary endpoint...
🔴 ACADIA Pharmaceuticals is trading 9.8% down in pre-market with no identified company-specific catalyst
ACADIA Pharmaceuticals is trading 9.8% lower at $22.95, with no fresh company-specific announcement identified to explain the pre-market decline. - Shares...
🔴 ACADIA Pharmaceuticals is trading 4.09% down today
ACADIA Pharmaceuticals is trading at $25.33, down -4.09% on September 23, 2026, with no fresh company-specific announcement identified to explain the...
🔴 ACADIA Pharmaceuticals is trading 22% down in after-hours trading with no clear catalyst identified
ACADIA Pharmaceuticals is trading at $20.61, down 21.96%, with no clear company-specific catalyst identified for the September 22, 2026 after-hours decline. -...
🔴 ACADIA Pharmaceuticals is trading 22.08% down in after-hours trading with no clear company-specific catalyst identified
ACADIA Pharmaceuticals is trading 22.08% down at $21.27 after-hours on September 18, 2026, with no clear company-specific announcement, earnings release, or...
🔴 ACADIA Pharmaceuticals is trading 5% down in pre-market as the catalyst remains unclear
ACADIA Pharmaceuticals is trading at $26.30, down -4.99%, with no clear company-specific negative announcement identified for September 10, 2026. - Recent...
🔴 ACADIA Pharmaceuticals is trading 4.12% down today despite biotech gains
ACADIA Pharmaceuticals is trading 4.12% down at $29.31 despite biotechnology’s 2.06% advance and broadly flat major indexes. - No new company-specific...
🟢 ACADIA Pharmaceuticals is trading 4.75% up in pre-market after European Commission grants DAYBU marketing authorization
ACADIA Pharmaceuticals is trading 4.75% up at $30.90 after the European Commission granted DAYBU marketing authorization for Rett syndrome symptoms in adults...
🔴 ACADIA Pharmaceuticals falls 4.1% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🟢 ACADIA Pharmaceuticals is trading 4% up today after UBS raised its price target to $49
ACADIA Pharmaceuticals is trading 4.03% up now at $30.18 after UBS raised its price target to $49 from $45 while reiterating a Buy rating. - UBS cited...
ACADIA Pharmaceuticals Price Target Raised by UBS on Optimism for Alzheimer's Drug Trial
UBS has increased its price target for ACADIA Pharmaceuticals Inc. to $49 from $45, while reiterating a 'Buy' rating for the stock. This new target is higher...